The William B. Abrams Lecture is a joint educational initiative of ASCPT and the FDA. The lecture series, supported in part by The Merck Company Foundation, was established in 1999 to honor William B. Abrams, MD, an ASCPT president from 1975 to 1976.
Among his many accomplishments, Dr. Abrams worked at the FDA as the first special government employee to establish the Center for Drug Evaluation and Research Staff College and develop its curriculum. He also had a distinguished career in the pharmaceutical industry as a longtime employee of Merck Research Laboratories.
For more than 10 years, ASCPT and the FDA have invited experts from academia, industry, and government to discuss advances in clinical pharmacology and drug development. These scientists have excelled in their specialty areas and are some of the most highly esteemed clinical pharmacologists in the field. Their presentations convey novel information and perspectives on fundamental aspects of clinical pharmacology. Previous lectures have included speakers from the Mayo Clinic, University of California, Children's Mercy Hospitals and Clinics, and the National Institutes of Health.
2019 ASCPT & FDA William B. Abrams Lecture
The 2019 ASCPT & FDA William Abrams Lecture Award recipient is Craig W. Hendrix, MD from Johns Hopkins University.
The lecture will place on Wednesday, June 5, 2019 (1-2:30 pm): Challenges Developing a Topical, On Demand, & Behaviorally-Congruent HIV Prevention Product
Additional choices for HIV pre-exposure prophylaxis, beyond oral daily PrEP, remain an acute need for persons at risk of HIV infection. On approach entails providing a topical rather than systemic, on demand rather than long-term daily or long-acting, and congruent with existing peri-coital behaviors rather than require new behaviors. The session will chronicle one approach to tackle each of these product development challenges in developing a rectal microbicide for HIV pre-exposure prophylaxis. This lecture is eligible for CE credits. Click here for full activity outline from the FDA.
After completion of this activity, the participant will be able to:
- Describe the clinical methods required to enable the development of a rectally-administered topical product designed for local action
- Give examples of early phase clinical studies guided by human-centered design built around peri-coital behaviors in order to prevent rectal acquisition of HIV.
If you would like to participate in the lecture remotely please register here: https://collaboration.fda.gov/cacsejune52019reg/event/registration.html
After you submit your registration you will receive and email confirming your registration. Please register before the lecture so that you will have time to test the Adobe Connect system requirements for the webcast.
If you have any questions about the ASCPT & FDA Abrams Award please contact Megan McBeath Hay